Biometrics: March 2014

MedNet To Showcase The iMedNet Partner Program At Partnerships in Clinical Trials 2014

MINNETONKA, Minn., March 26, 2014 /PRNewswire/ -- MedNet Solutions, a global life sciences technology company specializing in clinical study management systems, will once again be participating in the Partnerships in Clinical Trials conference. This year's event will be held March 30 – April 2 in Las Vegas, Nevada. Attendees are encouraged to visit MedNet's booth to see iMedNet EDC – an incredibly flexible and user friendly SaaS-based eClinical technology platform – and learn about the iMedNet Partner Program, created specifically to support the success of Clinical Research Organizations (CROs) and other healthcare consultants.

Key benefits of the iMedNet Partner Program include:

Predictable and Affordable Pricing Plus special partners-only discountsFull Sales and Marketing Support From sales training to prospective customer referralsiMedNet Advisory Forum Membership Ensuring partners' eClinical needs are fully addressed"This year's Partnerships conference will be an exciting one," noted John M. (Rob) Robertson, President and CEO of MedNet Solutions. "We'll have representatives on site to provide interested individuals with iMedNet demonstrations as well as more details about our iMedNet Partner Program. Since interest in our technology solutions and wrap-around support programs is growing rapidly, we anticipate a busy, but very productive few days."

Stay in touch with MedNet:

About MedNet Solutions
MedNet Solutions is a leading healthcare technology company specializing in electronic data capture (EDC) and clinical trial management systems (CTMS) designed for the global life sciences market. MedNet delivers proven, flexible and easy-to-use web-based eClinical solutions that effectively support clinical studies, registries and investigator initiated trials of all types and sizes. Since 2001, MedNet has successfully supported pharmaceutical, medical device, biotechnology and Contract Research Organizations (CROs) on clinical research conducted around the world. These companies trust MedNet to consistently deliver the technology innovation, experience and reliability they need for success. For more information, please visit www.mednetstudy.com.

Contact Information:
Dirk H. Nelson
Director of Marketing
110 Cheshire Lane, Suite 300
Minnetonka, MN 55305
USA
(763) 258-2735

SOURCE MedNet Solutions

RELATED LINKS
http://www.mednetstudy.com

reade more...

Patches of Cortical Layers Disrupted During Early Brain Development in Autism

SEATTLE, March 26, 2014 /PRNewswire/ -- Researchers at the University of California, San Diego School of Medicine and the Allen Institute for Brain Science have published a study that gives clear and direct new evidence that autism begins during pregnancy.

The study will be published in the March 26, 2014 online edition of the New England Journal of Medicine.

The researchers – by Eric Courchesne, PhD, professor of neurosciences and director of the Autism Center of Excellence at UC San Diego, Ed S. Lein, PhD, of the Allen Institute for Brain Science in Seattle, and first author Rich Stoner, PhD, of the UC San Diego Autism Center of Excellence – analyzed 25 genes in post-mortem brain tissue of children with and without autism. These included genes that serve as biomarkers for brain cell types in different layers of the cortex, genes implicated in autism and several control genes.

"Building a baby's brain during pregnancy involves creating a cortex that contains six layers," Courchesne said. "We discovered focal patches of disrupted development of these cortical layers in the majority of children with autism." Stoner created the first three-dimensional model visualizing brain locations where patches of cortex had failed to develop the normal cell-layering pattern.

"The most surprising finding was the similar early developmental pathology across nearly all of the autistic brains, especially given the diversity of symptoms in patients with autism, as well as the extremely complex genetics behind the disorder," explained Lein.

During early brain development, each cortical layer develops its own specific types of brain cells, each with specific patterns of brain connectivity that perform unique and important roles in processing information. As a brain cell develops into a specific type in a specific layer with specific connections, it acquires a distinct genetic signature or "marker" that can be observed.

The study found that in the brains of children with autism key genetic markers were absent in brain cells in multiple layers. "This defect," Courchesne said, "indicates that the crucial early developmental step of creating six distinct layers with specific types of brain cells – something that begins in prenatal life – had been disrupted."

Equally important, said the scientists, these early developmental defects were present in focal patches of cortex, suggesting the defect is not uniform throughout the cortex. The brain regions most affected by focal patches of absent gene markers were the frontal and the temporal cortex, possibly illuminating why different functional systems are impacted across individuals with the disorder.

The frontal cortex is associated with higher-order brain function, such as complex communication and comprehension of social cues. The temporal cortex is associated with language. The disruptions of frontal and temporal cortical layers seen in the study may underlie symptoms most often displayed in autistic spectrum disorders. The visual cortex – an area of the brain associated with perception that tends to be spared in autism – displayed no abnormalities.

"The fact that we were able to find these patches is remarkable, given that the cortex is roughly the size of the surface of a basketball, and we only examined pieces of tissue the size of a pencil eraser," said Lein. "This suggests that these abnormalities are quite pervasive across the surface of the cortex."

Researchers used data collected for the Allen Brain Atlas, as well as the BrainSpan Atlas of the Developing Human Brain, which was developed by a consortium of partners and funded by the National Institute of Mental Health. These rich resources allowed the scientific team to identify specific genes in the developing human brain that could be used as biomarkers for the different layer cell types.

Researching the origins of autism is challenging because it typically relies upon studying adult brains and attempting to extrapolate backwards. "In this case," Lein noted, "we were able to study autistic and control cases at a young age, giving us a unique insight into how autism presents in the developing brain."

"The finding that these defects occur in patches rather than across the entirety of cortex gives hope as well as insight about the nature of autism," added Courchesne.

According to the scientists, such patchy defects, as opposed to uniform cortical pathology, may help explain why many toddlers with autism show clinical improvement with early treatment and over time. The findings support the idea that in children with autism the brain can sometimes rewire connections to circumvent early focal defects, raising hope that understanding these patches may eventually open new avenues to explore how that improvement occurs.

Additional contributors to the study include Maggie L. Chow, PhD, and Subhojit Roy, MD, PhD, UC San Diego; Maureen P. Boyle, PhD, UC San Diego and Allen Institute; Peter R. Mouton, PhD, University of South Florida School of Medicine; Anthony Wynshaw-Boris, MD, PhD, Case Western Reserve University School of Medicine; and Sophia A. Colamarino, PhD, Stanford University School of Medicine.

This research was supported by funds from the Simons Foundation, the Peter Emch Family Foundation, Cure Autism Now/Autism Speaks, the Thursday Club Juniors, the UC San Diego Autism Center of Excellence (NIMH grant P50-MH081755), and the Allen Institute for Brain Science (NIMH grant RC2MH089921).

The BrainSpan Atlas of the Developing Human Brain was supported by Award Numbers RC2MH089921 (PIs Ed Lein & Michael Hawrylycz, Allen Institute for Brain Science), RC2MH090047 (PI James A. Knowles, University of Southern California) and RC2MH089929 (PI Nenad Sestan, Yale University), totaling $16.2M, $8.9M and $9.9M, respectively, from the National Institute of Mental Health. This project is funded with 100% federal funds. No non-government funds support the project. The content is solely the responsibility of the respective authors and does not necessarily represent the official views of the National Institute of Mental Health or the National Institutes of Health.

About the Allen Institute for Brain Science
The Allen Institute for Brain Science (www.alleninstitute.org) is an independent, 501(c)(3) nonprofit medical research organization dedicated to accelerating the understanding of how the human brain works in health and disease. Using a big science approach, the Allen Institute generates useful public resources used by researchers and organizations around the globe, drives technological and analytical advances, and discovers fundamental brain properties through integration of experiments, modeling and theory. Launched in 2003 with a seed contribution from founder and philanthropist Paul G. Allen, the Allen Institute is supported by a diversity of government, foundation and private funds to enable its projects. Given the Institute's achievements, Mr. Allen committed an additional $300 million in 2012 for the first four years of a ten-year plan to further propel and expand the Institute's scientific programs, bringing his total commitment to date to $500 million. The Allen Institute's data and tools are publicly available online at www.brain-map.org.

About UC San Diego Health Sciences
University of California, San Diego Health Sciences comprises clinical and academic entities – UC San Diego Health System, the region's only academic health system; UC San Diego School of Medicine, one of the nation's top research-intensive schools of medicine; and Skaggs School of Pharmacy and Pharmaceutical Sciences. The National Institutes of Health (NIH) ranks UC San Diego Health Sciences as one of the top two institutions in research funding per faculty member, and the School of Medicine is listed ninth in total NIH research funding. Part of the University of California system, UC San Diego – founded in 1960 – is renowned for collaborative and cross-disciplinary research that transcends traditional boundaries in science, engineering and the humanities.

Media Contacts:
Steven Cooper, Edelman for the Allen Institute for Brain Science
646.358.2765; Steven.Cooper@edelman.com

Scott LaFee, slafee@ucsd.edu
619.543.6163

SOURCE Allen Institute for Brain Science

RELATED LINKS
http://www.alleninstitute.org

reade more...

New York Healthcare Real Estate Conference - April 8 New York City: Join the Nation's Largest Healthcare Real Estate Investors, Developers, Capital Sources

"Healthcare real estate is now the darling of the industry. Learn more on April 8 during Healthcare & Real Estate 2014," Michael A. Noto , Senior Vice President--Management Services Group, Health Care REIT. (PRNewsFoto/CAPRATE Events)jwplayer.key="2kY/GKwZ2uQZmDlQ9VYArfZt2b4+KhHX3+DM4zisgtE=";NEW YORK, March 26, 2014 /PRNewswire-iReach/ -- Healthcare real estate is a hot real estate asset class in 2014! But just how hot and how real are the opportunities? Join the expected 400+ as we separate fact from fiction (and hype) at Healthcare & Real Estate 2014 on April 8 in New York.

Photo - http://photos.prnewswire.com/prnh/20140326/MN90408

Healthcare & Real Estate 2014 will bring together the most active and innovative national healthcare providers and real estate executives for vital discussion debate and networking. The opening panel "Healthcare Real Estate 20/20" will provide clear vision of the market today. The industry's top investors, developers, and healthcare providers will offer their thoughts on the many opportunities and challenges in the market. The many panels that follow will go beyond the headlines with pointed analysis and commentary on financing, the emergence of new investors and general healthcare service trends. Join 40+ speakers and the expected 400+ attendees for Healthcare & Real Estate 2014 on April 8.

> For additional information, including detailed agenda and registration: www.cre-events.com/hcre2014

Hear Active & Innovative Healthcare & Real Estate Executives, Including:
* Steve Anderson, Senior Vice President, Capital One Commercial and Specialty Finance
* Charles "Chick" Atkins, Principal, Atkins Companies
* James D. Bremner, President – Healthcare, Duke Realty
* Mark Burkemper, Senior Vice President, Harrison Street Real Estate Capital, LLC
* Jeffrey H Cooper, Chairman & Executive Managing Director, Savills
* Jeffrey P. Drucker, AIA, Vice President and Studio Director, Northeast Region, ARRAY
* Ciro Fraschilla, AIA, President & Chief Executive Officer, Mascioni & Behrmann, Architecture & Engineering, P.C.     * Wilkingson Germain, Investment Officer, Ventas, Inc.
* Scot Glasberg, MD, President Elect, American Society of Plastic Surgeons
* Morris Gross, Vice President – Facilities Management, Danbury Hospital    Amanda Houghton, Executive Vice President – Asset Management, Healthcare Trust of America, Inc.
* Todd Jensen, Chief Investment Officer, American Realty Capital Healthcare Trust
* Arthur Klein, MD, President, The Mount Sinai Health Network
* Christopher W. Korsh, Senior Principal – Regional Leader, Healthcare, HOK
* David P. Lari, Partner, Cox Castle Nicholson
* Steven Laufer, President, Promenade Senior Living
* Sean P. Leyden, Partner/Director, Garfunkel Wild, P.C.
* H. Guy Leibler, President, Simone Healthcare Development
* Andrew Lawler, Partner, Healthcare Development, The Keith Corporation
* John Marshall, Vice President, Duke Realty
* Chan-li Lin, Partner, Rafael Vinoly Architects
* Beth Burnham Mace, Chief Economist and Director of Capital Markets Outreach, National Investment Center for the Seniors Housing and Care Industry (NIC)
* Norman K. Livingston, Managing Partner, Founder, Norvin Partners, Ltd
* Scott A. Mason, D.P.A, FACHE, Executive Managing Director and Leader | Healthcare, Cushman & Wakefield
* Chris Montello, Principal, MP Healthcare Services
* Casey N. Moore, Principal, Prudential Mortgage Capital
* Jared Morgan, Vice President – Investments, SPIRIT Realty Capital
* Ken Music, Regional Manager, Bank of America
* Max Newland, Director – Acquisitions, Kayne Anderson Real Estate
* Michael A. Noto, Senior Vice President—Management Services Group, Health Care REIT
* Gary Sastow, Law Offices of Gary S. Sastow, PLLC
* Ronald M. Shapiro, Administrative Director, Rutgers Business School Center for Real Estate Studies

* James F Sherman, Executive Vice President – Seniors Housing, Beech Street Capital
* Frank R. Williams, Jr., Senior Managing Director – Acquisitions, Medical Properties Trust, Inc.
* Paul Wexler, Wexler Healthcare Properties, The Corcoran Group
* Salley Whitman, Co-Founder & Executive Director, NXT Health
* Jonathan L. Winer, Senior Managing Director and Chief Investment Officer, Seavest Healthcare Properties, LLC
* Murray Wolf, Publisher, Healthcare Real Estate Insights
* Laca Wong Hammond, Head of Healthcare Real Estate – Healthcare Investment Banking, Raymond James

* Jonathan Buehner, GE Capital Healthcare Financial Services
* Paul N. Orloff, MD, President, New York County Medical Society

NETWORKING & NEW BUSINESS DEVELOPMENT: 225 leading CRE and healthcare executives from 95 firms have already made plans to attend. Attending firms, as of March 24, 2014:
* AFD Contract Furniture Inc.
* American Realty Capital
* American Society of Plastic Surgeons
* Andersen Environmental
* Arbor Commercial Mortgage
* ARRAY
* Array Architects
* Atkins Companies
* Bank of America
* Beech Street Capital
* Bergman Real Estate Group
* Bohler Engineering
* Capital One
* Caracor LLC
* CBRE
* Cox, Castle & Nicholson LLP
* CTL Capital
* Cushman & Wakefield
* Danbury Hospital
* Dare Living Associates
* Duke Realty
* EmblemHealth, Inc.
* EwingCole
* First Columbia Property Services
* Garfunkel Wild, P.C.
* GE Capital – Healthcare Financial Services
* Gilsanz Murray Steficek, LLP
* Grassi & Co.
* Harrison Street Real Estate Capital, LLC
* Health Care REIT, Inc.
* HealthAmerica Realty Group
* Healthcare Real Estate Insights
* Healthcare Trust of America, Inc.
* HFF
* HOK
* JFK&M Consulting Group
* Kayne Anderson Real Estate
* Kings III Emergency Communications
* Law Offices of Gary S. Sastow, PLLC
* LifeQuest
* Lillibridge Healthcare Services
* LJS Real Estate Services
* LotInfo LLC
* LPCiminelli
* Marcus & Millichap Real Estate Investment Services
* Mascioni & Behrmann, Architecture & Engineering, P.C.
* MB Real Estate
* MedDev LLC
* Medical Properties Trust, Inc.
* Memorial Sloan Kettering Cancer Center
* Meritage Properties LLC
* Montefiore
* MP Healthcare Services
* NAI JAMES E. HANSON
* National Investment Center for the Seniors Housing and Care Industry (NIC)
* Nelin Real Estate Management, Inc.
* New York County Medical Society
* Newmark Associates, Commercial Real Estate Services
* NIC
* NK Architects
* NK Associates
* Norvin Partners, Ltd
* NPV Advisors
* NXT Health
* OMNInteriors
* Penn Real Estate Group
* Perkins+Will
* Platinum Health Care, LLC
* Promenade Senior Living
* Prudential Mortgage Capital
* Prudential Mortgage Capital Company
* Rafael Vinoly Architects
* Raymond James
* Rutgers Business School Center for Real Estate Studies
* Savills LLC
* Seavest Healthcare Properties, LLC
* Simone Development
* Simone Healthcare
* Simone Healthcare Development
* Simpson Gumpertz & Heger
* Spirit Realty Capital Inc.
* Stan Johnson Company
* Starwood Capital Group
* Stephen Yablon Architect
* Suburban Hospital Alliance
* Suffolk Construction Co., Inc.
* The Keith Corporation
* The Mount Sinai Health Network
* The Real Deal
* Trammell Crow Company
* Vanderweil Engineers
* Ventas, Inc.
* Voikos Construction Management
* Westage Companies
* Wexler Healthcare Properties, The Corcoran Group
* Windels Marx Lane & Mittendorf, LLP
* Yang & Associates, P.C.

Event Speaker/Sponsor Contact: Brian Klebash | 917-460-3572 | info@cre-events.com

CapRate Events/CRE-Events.com is an independently-owned and operated digital media firm based in New York City. Launched in June of 2011, the firm has emerged as a new leader in commercial real estate informational and networking services.

Media Contact: Brian Klebash, CAPRATE Events, LLC, 6175016075, info@cre-events.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com

SOURCE CAPRATE Events

reade more...

Marvin Test Solutions Announces New AIM-120 Simulation and Test Capabilities for MTS-3060 SmartCan™ Armament Test Set

IRVINE, Calif., March 25, 2014 /PRNewswire/ -- Marvin Test Solutions (formerly known as Geotest-Marvin Test Systems) a global provider of innovative test solutions for military, aerospace, and manufacturing organizations, today announced new enhancements to its MTS-3060 SmartCan™, a universal O-level aircraft armament test set for legacy aircraft employing smart weapons. With the new SmartCan™ enhancements, maintainers now can test the full functionality of the AIM-120 interface by emulating the missile.

Overcoming Obsolescence
Today, 4th and 5th generation aircraft, like the F-16, are equipped with smart (MIL-STD 1553 and 1760) weapons technology and enhanced legacy weapons. These aircraft demand rapid, on-aircraft test and troubleshooting capabilities, a simplified test process, and a smaller test footprint on the flightline to ensure efficient operation. Currently, armament circuits preload test sets (ACPTS) require additional, big-box test equipment test equipment to fully and accurately verify that sophisticated armament and munitions systems are full mission-capable (FMC), and in some cases, this combination can't even meet testing requirements. Therefore, maintainers need new testing capabilities to support today's smart weapons, including interfaces such as AIM-120.

With the compact SmartCan™ test set, Marvin Test Solutions aims to meet the testing needs of today's smart weapons while overcoming system obsolescence. SmartCan™ is capable of standardizing and consolidating armament test equipment across 4th and 5th generation aircraft, including F-5, Hawk, TA/ FA-50, A-10, F-15, F-16, and F-18.

"SmartCan™, a test set that is capable of testing not only the continuity, but also the functionality of the MIL-STD-1760 bus ensures higher mission readiness and lowers the cost of flightline equipment," said Major General Steve Sargeant, USAF (Ret.) and CEO of Marvin Test Solutions. "Our new test capabilities for AIM-120 enhance the capabilities of the proven SmartCan™, a platform already successfully qualified and deployed on F-5, Hawk, TA/ FA-50, F-16 Block 15 and Block 50, and F-15C aircraft. These capabilities have been globally recognized by organizations including the Air National Guard, which is now including the SmartCan™ in a pending evaluation of flightline test equipment for the F-16."

Improving Flightline Test
The MTS SmartCan™ is the only flightline test set capable of fully emulating smart weapons such as JDAM during pre-load armament test. Furthermore, it is the only test set to evaluate the full functionality of the MIL-STD-1760 bus interface between the armament and aircraft. With the new SmartCan™ enhancements, maintainers now can test the full functionality of the AIM-120 interface by emulating the missile.

The hand-held, AA battery-operated SmartCan™ universal flightline test set weighs less than three pounds and packs the capability to conduct full pre- and post-load operations as well as possessing pre- and post-flight audio and video channels for troubleshooting legacy systems such as AIM-9 and AGM-65. It can be tailored and expanded to accommodate armament loaded on any 4th or 5th generation aircraft, and can troubleshoot many of the problems encountered by maintainers.

Bringing O-Level Test to FIDAE 2014
Marvin Test Solutions will showcase SmartCan™ and other armament test solutions at FIDAE 2014, March 25-28 in Santiago, Chile.

Major General Steve Sargeant, USAF (Ret.), CEO of Marvin Test Solutions will be available at FIDAE 2014 to meet with leaders in the military and aerospace industry and discuss how Marvin Test Solutions can enhance their ability to maintain and sustain aircraft, while simultaneously replacing obsolete legacy test equipment. The company will be joining its distributor, Aero Precision, in booth C-14.

To make an appointment to meet with General Sargeant at FIDAE 2014, contact Donna Van Dyke at DonnaV@marvintest.com or Lori Lai at LoriL@marvintest.com. For more information on Marvin Test Solutions equipment offerings visit marvintest.com.

About Marvin Test Solutions
Marvin Test Solutions, a vertically integrated aerospace test and measurement company, has delivered innovative, feature-rich test solutions meeting for factory, flightline, intermediate-level, and depot-level requirements since 1988. As a member of the Marvin Group, an award-winning aerospace group with a 50-year history in the Military and Commercial Aerospace industries, Marvin Test Solutions has test equipment deployed in support of most of the major defense aircraft and munitions in use around the world. Marvin Test Solutions quickly delivers full-spectrum, successful test solutions making test, maintenance, and sustainment of the most mission-critical systems easier and faster.

Media/Customer Contact: Lori Lai, loril@marvintest.com

SOURCE Marvin Test Solutions

Global Imaging biomarkers market 2014-2018

DUBLIN, 25 March of 2014/PRNewswire /-

Research and markets (http://www.researchandmarkets.com/research/tp3h3r/global_imaging) has announced the addition of the report "Global Imaging biomarkers market 2014-2018" to its offer.

(Logo: http://photos.prnewswire.com/prnh/20130307/600769)

Prognosis of analysts of the market Global Imaging biomarkers to grow at a CAGR of 15.09 percent in the period 2013-2018. One of the key factors contributing to this growth of the market is the increasing prevalence of cancer. Biomarkers of image Global market has also witnessed the emergence of personalized medicine. However, the poor regulatory and reimbursement systems could pose a challenge to the growth of this market.

The report, Global Imaging biomarkers market 2014-2018, based on an in-depth analysis of the market with input from industry experts. The report covers the market in the Americas and the regions EMEA and APAC; also covers the landscape of market Global Imaging biomarkers and their prospects for growth in the coming years. The report also includes a discussion of the main vendors operating in this market.

Biomarkers of image Global market has witnessed an increase in the number of partnerships formed between the organizations strategic. Mergers and acquisitions help organizations quickly grow, expand their business processes and gain more market share. The introduction of technologies in small and medium-sized enterprises is leading to major pharmaceutical and biotech companies to form strategic alliances with these smaller companies to identify different biomarkers of image.

The increase in alliances is resulting in an increase in the base application for imaging biomarkers in domains of discovery and diagnosis of drugs. For example, in 2012, Genomic Health Inc. and OncoMed Pharmaceuticals announce a strategic alliance for the research of biomarkers and discovery through the process of next-generation sequencing.

According to the report, the use of imaging biomarkers in the field of drug discovery has increased considerably in recent years. The increase in the demand for imaging biomarkers is mainly due to its ability to be used in white discovery and validation, identification of proof-of-concept studies, toxicity profiles and disease mechanisms.

In addition, the report notes that one of the main challenges that hinder the growth of this market is the presence of poor regulatory and reimbursement systems. Reimbursement systems present in several countries and current regulators are not suitable for imaging Diagnostics based on biomarkers. The development of novel and useful image biomarkers is also a costly and time-consuming process of time.

The study was carried out with a combination of objective of primary data and secondary, including contributions from key players in the industry. The report contains a broad market and vendor landscape as well as a SWOT analysis of key suppliers.

Key songs covered:

1. Executive summary

2. list of abbreviations

3. scope of the report

4 methodology of market research

5 introduction

6. market landscape

7. geographic segmentation

8 buying criteria

9 market growth drivers

10 drivers and its impact

11. the challenges of the market

12. the impact of drivers and challenges

13. the trends of the market

14 trends and its impact

15 vendor landscape

16. key supplier analysis

17. other reports in this series

Companies mentioned:

Abbott LaboratoriesAgilent Technologies Inc.Affymetrix Inc.Bio-Rad Laboratories Inc.F. Hoffmann the Roche Ltd.Gen-Probe Inc.Siemens Healthcare.
For more information visit http://www.researchandmarkets.com/research/tp3h3r/global_imaging

Media contact: Laura Wood, + 353-1-481-1716, press@researchandmarkets.net

Markets and supply research

reade more...

Global Market bioinformatics 2014-2018

DUBLIN, 25 March of 2014/PRNewswire /-

Research and markets (http://www.researchandmarkets.com/research/53bwxk/global) has announced the addition of the report "Global bioinformatics" market 2014-2018 to its offer.

(Logo: http://photos.prnewswire.com/prnh/20130307/600769)

Prognosis of analysts of the Global bioinformatics market to grow at a CAGR of 26.15 per cent in the period 2013-2018. One of the key factors contributing to this growth of the market is the reduction in the cost of genetic sequencing. The Global bioinformatics market has also witnessed the growing outsourcing of bioinformatics. However, the complexity in the use of bioinformatics tools could pose a challenge to the growth of this market.

Prepared the report, bioinformatics market 2014-2018 Global, based on an in-depth analysis of the market with input from industry experts. The report covers the Americas and the region of EMEA and APAC; It also covers the landscape of Global bioinformatics market and prospects for growth in the coming years. The report also includes a discussion of the main vendors operating in this market.

As a result of declining budgets for R & D, biotechnology companies and other organizations are looking for ways to increase efficiency through the outsourcing bioinformatics to effectively support its R & D activities at a lower cost. In addition, outsourcing may be a more viable option for research organizations that lack the necessary knowledge of infrastructure and computational computing for bioinformatics tools in house. Outsourcing of services from a third-party provider may allow an organization focus on key projects that contribute to increase the effectiveness of its R & D and shorten terms of desarrollo-a - launch.

According to the report, one of the main drivers in this market is the reduction in the cost of genetic sequencing. This cost reduction is the result of the development of tools and technologies, as well as improvements in the processes carried out by researchers of genomics.

In addition, the report notes that one of the biggest challenges in the market is the increasing complexity in the use of bioinformatics tools and the consequent need for adequate training and orientation to use these tools properly and efficiently.

Key songs covered:

1. Executive summary

2. list of abbreviations

3. scope of the report

4 methodology of market research

5 introduction

6. market landscape

7 segmentation by application

8. segmentation of products and services

9. geographic segmentation

10 buying criteria

11 market growth drivers

12. the drivers and its impact

13. the challenges of the market

14. the impact of drivers and challenges

15. the trends of the market

16 trends and its impact

17 vendor landscape

18. the leading analysis providers

19. other reports in this series

Companies mentioned:

Accelrys Inc.Affymetrix Inc.Agilent Technologies Inc.Biobase GmbHBiomatters Ltd.Biotique Inc.CLCbio A/S and Illumina Inc.Cartagenia systems n.v.Conexio-GenomicsDNASTAR Inc.Genedata AGGeneva bioinformatics Software Inc.Genomatix Software GmbHMolecular life sciences SAGenoLogics networks GmbHPerkinElmer Inc.SmartGene Services SARL.

For more information visit http://www.researchandmarkets.com/research/53bwxk/global

Media contact: Laura Wood, + 353-1-481-1716, press@researchandmarkets.net

Markets and supply research

reade more...

Global Commercial Airports Body Scanners Market

DUBLIN, March 24, 2014 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/zb2kpd/global_commercial) has announced the addition of the "Global Commercial Airports Body Scanners Market " report to their offering.

(Logo: http://photos.prnewswire.com/prnh/20130307/600769 )

The analysts forecast the Global Commercial Airport Full Body Scanner market to grow at a CAGR of 6.74 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing threat of terrorist attacks. The Global Commercial Airport Full Body Scanner market has also been witnessing the pilot testing of full body scanning machines in the APAC region. However, Islamic countries' refusal to use body scanners could pose a challenge to the growth of this market.

The report, the Global Commercial Airport Full Body Scanner Market 2012-2016, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market in the Americas, and the EMEA and APAC regions; it also covers the Global Commercial Airports Body Scanners market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

In recent years, full-body scanners are increasingly being used in pilot projects in several airports in the APAC region. Many commercial airports in the APAC region are installing full-body scanners and initiating pilot programs to test the feasibility of using these advanced devices. Full-body scanners are currently being used in trial phases in airports such as the Changi International Airport, Beijing International Airport, Delhi International Airport, Narita International Airport, Incheon International Airport, as well as the Sydney and Melbourne International Airports. Combined with other technologies, these devices could be permanently used in the passenger screening procedures at these airports, thereby fostering the growth of the market during the forecast period.

According to the report, one of the major drivers in this market is the increasing threat of terrorist attacks across the globe. The 9/11 terrorist attack has prompted the TSA to tackle the issue of security with utmost seriousness, and hence it has employed full-body scanners for screening passengers at major airports.

Further, the report states that one of the major challenges in this market is the resistance to the use of body scanners in Islamic countries. Many Islamic nations are against the idea of installing full-body scanner because it violates their religious beliefs.

The report also includes a discussion of the other vendors operating in this market. The other vendors in the market are CST Digital Communication (Pty) Ltd., Braun International Ltd., Tek84 Engineering Group, Morpho SA, and Smiths Detection Inc.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

Key Topics Covered:

1. Executive Summary
2. List of Abbreviations
3. Introduction
4. Market Research Methodology
5. Scope of the Report
6. Market Landscape
7. Geographical Segmentation
8. Key Leading Countries
9. Vendor Landscape
10. Buying Criteria
11. Market Growth Drivers
12. Drivers and their Impact
13. Market Challenges
14. Impact of Drivers and Challenges
15. Market Trends
16. Key Vendor Analysis
17. Other Reports in this Series

Companies Mentioned:

American Science and Engineering Inc.L-3 Communications Holdings Inc.Microsemi Corp.Rapiscan Systems Inc.For more information visit http://www.researchandmarkets.com/research/zb2kpd/global_commercial

Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net

SOURCE Research and Markets

reade more...

Event Alert: Kinaxis Executive to Present "Continuous S&OP - Breaking the Mold" at LogiPharma Europe 2014

www.kinaxis.com. (PRNewsFoto/Kinaxis)jwplayer.key="2kY/GKwZ2uQZmDlQ9VYArfZt2b4+KhHX3+DM4zisgtE=";OTTAWA, Ontario, March 24, 2014 /PRNewswire/ -- Kinaxis®, provider of RapidResponse®, a cloud-based SCM and S&OP service, is proud to be a sponsor of LogiPharma 2014, which will be held April 8 – 9, 2014 at the Congress Center Basel in Basel, Switzerland.

Event Details
Join Trevor Miles, vice president of thought leadership and industry principle, life sciences at Kinaxis on Wednesday, April 9th, 2014 at 3:55p.m., as he presents "Continuous S&OP – Breaking the Mold". In this session, he will discuss how business and technology has changed tremendously in the thirty years since S&OP was first defined, enabling much more proficient and integrated S&OP processes. Trevor will describe how companies are breaking the traditional S&OP mold from both a process and technology perspective. In addition, Mr. Miles will moderate a roundtable discussion: "Leveraging the Cloud to Achieve True Innovation in Supply Chain Management" on Tuesday, April 8th at 4:15p.m.

During the conference follow hashtag #LogiPharma and stop by the Kinaxis booth #21 to meet with the team and learn more about how Kinaxis has helped life science companies adopt process improvements and technology targeted at removing business "silos," improving collaboration, and achieving significant operations performance breakthroughs. Find out more about RapidResponse for life sciences at: http://kinax.is/pharm.

For more Kinaxis news, follow us on LinkedIn, Twitter or Facebook.

About Kinaxis
Kinaxis delivers cloud-based S&OP and supply chain solutions for discrete manufacturers and brand owners with complex supply chain networks and volatile business environments. Leaders across multiple industry verticals, including A&D, Automotive, High Tech, Industrial and Life Sciences rely on RapidResponse for concurrent planning, continuous performance monitoring, and coordinated responses to plan variances across multiple areas of the business. RapidResponse's configurable service solutions encompass a full spectrum of supply chain related business processes, including such functions as: S&OP, supply planning, capacity planning, demand planning, inventory management, MPS and order fulfillment. As a result, Kinaxis customers have replaced disparate planning and performance management tools and are realizing significant operations performance breakthroughs in planning cycles, supply chain response times and decision accuracy. From a single product, customers are able to easily model varying supply chain conditions to make both long-term and real-time demand and supply balancing decisions quickly, collaboratively, and in line with the shared business objectives of multiple stakeholders.

Contact:
Melissa Clow
mclow@kinaxis.com

Logo - http://photos.prnewswire.com/prnh/20120208/CG49456LOGO-b

SOURCE Kinaxis

Protein Metrics Expands Biopharmaceutical Software Suite with Launch of Byomap™ Software

Protein Metrics Byomap(TM) software, developed in close collaboration with biopharmaceutical researchers, facilitates quick annotation of peptide maps and rapid, quantitative comparison of multiple data traces against a reference material. ...jwplayer.key="2kY/GKwZ2uQZmDlQ9VYArfZt2b4+KhHX3+DM4zisgtE=";SAN CARLOS, Calif., March 24, 2014 /PRNewswire-iReach/ -- Protein Metrics Inc., a leading provider of software for rapid and thorough protein characterization, today announced the release of Byomap™ software for advanced peptide mapping. Byomap facilitates quick annotation of peptidemaps and rapid, quantitative comparison of multiple data traces against a reference material. Byomap is an extension of Protein Metrics' biopharmaceutical suite of products that includes their Byologic™ software, which enables researchers to confidently characterize their product down to trace components identifying degadants, impurities, post-translational modifications and sequence variants.

(Photo: http://photos.prnewswire.com/prnh/20140324/MN87673)

"We are excited to expands our biopharmaceutical portfolio and provide a new, advanced peptide mapping tool to help biopharmaceutical researchers characterize their therapeutic proteins," said Chris Becker, Ph.D., President and CEO of Protein Metrics. "Byomap's convenient annotation and comparison capabilities enable our customers to quickly report on comparability and advance their Quality by Design (QbD) initiatives to track quality attributes as their products move through development."

Originally developed in close collaboration with biopharmaceutical researchers, Byomap begins the quantitative evaluation of chromatograms by first detecting peaks, then performing automatic baseline and peak area determinations. Annotation is rapid with the aid of novel visualization tools. Byomap can simultaneously align and quantitatively compare up to ten peptide maps to an annotated reference map, flagging peaks with out-of-tolerance intensities. It can also be used to analyze other types of chromatograms such as for detached glycans. The software has sophisticated export features for figures and tables that can be used directly in regulatory filings.

About Protein Metrics

Protein Metrics is a privately held software company serving biopharmaceutical development professionals and proteomics researchers. The company focuses on the analysis of mass spectrometric and other analytical data on proteins and glycans. Seeking to ensure that software to analyze mass spec and other analytical data keeps pace with the rapid advances in analytical instrumentation, Protein Metrics leverages its experience in analytical chemistry, bioinformatics, and computer science to make analytical results more complete, sensitive, accurate, and easier to achieve. Protein Metrics products are built on collaborations with pharmaceutical research scientists and years of research on proteins and glycans. The company is headquartered in San Carlos, California. For more information, visit www.proteinmetrics.com.

Media Contact: Eric Carlson, Protein Metrics, Inc., 408-600-5540, carlson@proteinmetrics.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com

SOURCE Protein Metrics, Inc.

RELATED LINKS
http://www.proteinmetrics.com

reade more...

Patient Advocates And Social Workers Will Be Trained On Intricacies Of Affordable Care Act With CSL Behring Grant

CSL Behring logo. (PRNewsFoto/CSL Behring)jwplayer.key="2kY/GKwZ2uQZmDlQ9VYArfZt2b4+KhHX3+DM4zisgtE=";KING OF PRUSSIA, Pa., March 24, 2014 /PRNewswire/ -- Navigating the complexities of the Affordable Healthcare Act (ACA) can be challenging, particularly where patients with chronic medical disorders such as hemophilia and von Willebrand disease are concerned. CSL Behring is awarding a Local Empowerment for Advocacy Development (LEAD) grant to help bleeding disorder patients develop a clearer understanding of ACA and potential areas of concern.

The grant will enable Hemophilia of Indiana to help close the information gap by providing training for National Hemophilia Foundation (NHF) chapter staff and hemophilia treatment center (HTC) social workers in five states – Indiana, Michigan, Wisconsin, Illinois and Missouri. The training will address the following areas:

Issues related to the implementation of the ACA as they pertain to people with bleeding disorders. How to assist those with specific chronic health conditions and help to ensure their needs are fully met under the ACA's 10 "essential health benefits." How to examine whether a person's insurance coverage, particularly coverage provided through new exchanges, provides a sufficient array of providers (including HTCs) and defined standards that meet those that patients had obtained prior to the passage of ACA.After completing the training, it is expected that HTC and NHF staff will have greater understanding of specific issues around ACA implementation that impact the quality of healthcare insurance coverage of people with bleeding disorders. Staff will also be better equipped to monitor ACA implementation to identify areas of specific concern for people with bleeding disorders.

In addition, HTC social workers will be more knowledgeable about the ACA and will be able to answer consumers' questions in an accurate and timely manner. Lastly, the participants will be trained to develop action steps and an advocacy plan for consumers to guide their efforts to secure desired insurance coverage, particularly with regard to plans that provide the best coverage for clotting factor. The training will be held in August in Indianapolis.

Dennis Jackman, CSL Behring's senior vice president for global healthcare policy and external affairs, said selecting the best coverage for clotting factor can be particularly challenging. "The implementation of ACA could pose a substantial shift in how people are insured. Individuals in the states will have many different plans, some that are part of a state exchange, others that are part of a federal exchange, and still more plans that are a combination of the two, depending on the state. Our goal is to help assure that patients and their caregivers have as much information as possible to assist them in making decisions that are in their best interests."

Scott Ehnes, executive director of Hemophilia of Indiana, said the grant from CSL Behring is essential to the success of the project. "As the details of this complex healthcare insurance reform initiative become clear, the LEAD grant will enable us to conduct training that addresses areas of concern that are identified as the ACA is implemented, such as issues around the healthcare exchanges."

CSL Behring also awarded a LEAD grant to facilitate the formation of the Texas Bleeding Disorders Coalition, comprised of three existing patient groups: Texas Central Hemophilia Association, the Lone Star Chapter of NHF, and the El Paso Chapter of NHF. Jackman emphasized the importance of speaking with one voice on behalf of bleeding disorder patients in Texas. "We are happy to support this effort, which will hopefully enable them to expand on their already successful advocacy efforts."

A third LEAD grant is being awarded to the Louisiana Hemophilia Foundation to establish a dynamic advocacy program that enables the members of Louisiana's bleeding disorders community to take a more active role in advocating for access to care.

CSL Behring has awarded 51 LEAD grants to patient advocacy organizations totaling more than $630,000 since the program was established in 2008. Proposals are being accepted for the next grant cycle. The deadline for submitting a proposal is April 30, 2014.

About CSL Behring

CSL Behring is a leader in the plasma protein therapeutics industry. Committed to saving lives and improving the quality of life for people with rare and serious diseases, the company manufactures and markets a range of plasma-derived and recombinant therapies worldwide.

CSL Behring therapies are used around the world to treat coagulation disorders including hemophilia and von Willebrand disease, primary immune deficiencies, hereditary angioedema and inherited respiratory disease, and neurological disorders in certain markets. The company's products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent hemolytic diseases in the newborn.

CSL Behring operates one of the world's largest plasma collection networks, CSL Plasma. CSL Behring is a global biopharmaceutical company and a member of the CSL Group of companies. The parent company, CSL Limited (ASX:CSL), is headquartered in Melbourne, Australia. For more information, visit http://www.cslbehring.com/.

Contact:
Chris Florentz, CSL Behring
610-878-4316
Christopher.Florentz@cslbehring.com

Logo - http://photos.prnewswire.com/prnh/20100914/PH63692LOGO

SOURCE CSL Behring

From DNA To Diagnosis: USTAR Center For Genetic Discovery To Integrate Genome Data Into Patient Care

University of Utah Health Sciences Logo. (PRNewsFoto/Huntsman Cancer Institute at the University of Utah)jwplayer.key="2kY/GKwZ2uQZmDlQ9VYArfZt2b4+KhHX3+DM4zisgtE=";SALT LAKE CITY, March 24, 2014 /PRNewswire-USNewswire/ -- The USTAR Center for Genetic Discovery is partnering with California based Omicia, Inc, to make analyzing a patient's genome as routine as performing a blood test. The center, co-directed by Mark Yandell, Ph.D., and Gabor Marth, D.Sc., was launched this month with $6 million from the University of Utah and the state-funded Utah Science Technology and Research (USTAR) initiative.

Compared to 10 years ago, sequencing the human genome has plummeted in cost by 1 million-fold and can be completed in a fraction of the time. Yet there are still barriers preventing DNA sequence information from routinely being incorporated into patient care.

"Current systems are not prepared for the increasing amounts of data we will be seeing within the next few years," said Marth, a computer scientist who was instrumental in the success of high profile projects such as the Human Genome Project, HapMap Project, and 1,000 Genomes Project. He relocated to the University of Utah from Boston College to apply his skills in a medical setting.

"At some point all of humanity will be sequenced, and potentially more than one genome per individual," he continued. Marth and Yandell will lead efforts to tame the big data to come not only from personal genomes, but also tumor genomes and "metagenomes" from infectious disease agents such as viruses and bacteria.

Knowing the DNA sequence of a cancer patient's tumor, for example, may reveal a personalized treatment plan for combating the disease. Pinpointing tiny sequence variations in personal genomes will expose inherited diseases that, in some cases, may be life-threatening.

"What we want to be able to do is help the kid who is born with a hard-to-diagnose genetic disorder," said Yandell. "Our genome interpretation tools will be able to identify that disorder and guide treatment."

Together with Omicia, Inc., the USTAR Center for Genetic Discovery is building a web accessible informatics platform, called Opal, to distill genome data to clinically relevant findings. Opal is powered by VAAST, a proven disease gene finder algorithm invented by Yandell. Launched less than two years ago, VAAST has successfully identified causes of inherited diseases, including hard-to-diagnose rare diseases, and is used at 251 institutions worldwide.

The USTAR Center for Genetic Discovery eventually anticipates commercializing its full suite of software tools, and becoming a top genomic health data service provider for medical centers nationwide.

Listen to an interview with Gabor Marth.

This news release was issued on behalf of Newswise(TM). For more information, visit http://www.newswise.com.

Logo - http://photos.prnewswire.com/prnh/20140205/DC59634LOGO

SOURCE University of Utah Health Sciences

RELATED LINKS
http://healthcare.utah.edu

reade more...

Image Recognition Market worth $25.65 Billion by 2019

DALLAS, March 24, 2014 /PRNewswire/ --

The report "Image Recognition Market [Method (OCR, Object, Pattern Matching, Barcode/ QR, Facial), Application (Security & Surveillance, Quality Control & Inventory Management, Advertising, Scanning & Imaging, m-Commerce)] - Worldwide Market Forecast (2014-2019)", defines and divides the Image Recognition Market into various sub segments along with a detailed analysis and forecasting of segment-wise revenues. It also explains the drivers and restraints for this market and identifies the opportunities, challenges, and ongoing trends.

Browse more than 72 market data tables with 16 figures spread through 187 pages and in-depth TOC on "Image Recognition Market"

http://www.marketsandmarkets.com/Market-Reports/image-recognition-market-222404611.html

Early buyers will receive 10% customization on this report.

Today, the image recognition solutions are not only fulfilling basic human requirements, such as purchasing numerous products through smartphone-based applications, but are also providing state-of-the-art technology facilitated equipment for sensitive layouts such as defense, airports, immigration, and customs departments. Also, the Intelligent Character Recognition (ICR) technology is used in sorting and enumerating important files for organizational purposes. It helps in accessing a particular document with ease and saving time.

MarketsandMarkets has comprehensively divided the Image Recognition Market by types: Optical Character Recognition (OCR), pattern and gradient matching, object recognition, barcode/QR code recognition, facial recognition; by components: hardware, software, and services; by deployment: on-premise and on-demand; by applications: security and surveillance, marketing and promotional activities, content management, advanced driving assistance, quality control and inventory management, scanning and imaging, m-commerce, and others; by verticals: government and defense, Banking, Financial services, and Insurance (BFSI), healthcare and life sciences, manufacturing/industrial units, consumer goods and retail, IT and telecommunication, transport and logistics and others; by regions: North America (NA), Europe (EU), Asia-Pacific (APAC), Latin America (LA) and Middle East and Africa (MEA).

MarketsandMarkets believes that there is a lack of user awareness and a few technological quality issues in the Image Recognition Market. These challenges are restraining businesses and customers from implementing image recognition technology to support a broad spectrum of applications, such as security and surveillance, marketing and promotional activities, content management, advanced driving assistance, quality control and inventory management, scanning and imaging, and m-commerce.

The Image Recognition Market is estimated to grow from $9.65 billion in 2014 to $25.65 billion by 2019 at a Compound Annual Growth Rate (CAGR) of 21.6% from 2014 to 2019. NA is the biggest market for image recognition solutions while other regions such as APAC and MEA are expected to increase with high CAGRs.

Browse Related Reports

Facial Recognition Market [Emotion; Thermal; Mobile; Forensic; 2D; 3D; Cloud-based Facial Recognition]: Global Advancements, Emerging Applications, Business Models, and Worldwide Market Forecasts and Analysis (2013-2018)

http://www.marketsandmarkets.com/Market-Reports/facial-recognition-market-995.html

Thermal Imaging Market [Surveillance (Airborne, Maritime, Land), Threat Detection, Surveys, Automation, Radiology, ITS, Commercial Security, Personal Vision, Firefighting, R&D, Veterinary, Automotive]: Worldwide Market Forecasts 2013-2018

http://www.marketsandmarkets.com/Market-Reports/thermal-imaging-market-1300.html

About MarketsandMarkets

MarketsandMarkets is a global market research and consulting company based in the U.S. We publish strategically analyzed market research reports and serve as a business intelligence partner to Fortune 500 companies across the world.

MarketsandMarkets also provides multi-client reports, company profiles, databases, and custom research services. MarketsandMarkets covers thirteen industry verticals; including advanced materials, automotives and transportation, banking and financial services, biotechnology, chemicals, consumer goods, telecommunications and IT, energy and power, food and beverages, industrial automation, medical devices, pharmaceuticals, semiconductor and electronics, aerospace & defense.

We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository.

Contact:

Mr. Rohan
North - Dominion Plaza
17304 Preston Road
Suite 800, Dallas, TX 75252
Tel: +1-888-600-6441
Email: sales@marketsandmarkets.com

Visit MarketsandMarkets Blog @ http://www.marketsandmarketsblog.com/market-reports/telecom-it

Connect with us on LinkedIn @ http://www.linkedin.com/company/marketsandmarkets

SOURCE MarketsandMarkets

reade more...

ACC Mascots Visit Brenner Children's Hospital

The mascots of the Atlantic Coast Conference spent some time at Brenner Childrenâ??s Hospital, part of Wake Forest Baptist Medical Center, in Winston-Salem, N.C. on Friday, March 14. They stopped by as part of an outreach initiative for the 2014 ACC ...jwplayer.key="2kY/GKwZ2uQZmDlQ9VYArfZt2b4+KhHX3+DM4zisgtE=";WINSTON-SALEM, N.C., March 14, 2014 /PRNewswire/ -- The mascots of the Atlantic Coast Conference spent some time at Brenner Children's Hospital, part of Wake Forest Baptist Medical Center, in Winston-Salem, N.C. on Friday, March 14. They stopped by as part of an outreach initiative for the 2014 ACC Men's Basketball Tournament. Young patients got to meet and have their photos taken with their favorite mascots during the visit. A good time was had by all, especially the mascots who seemed to thoroughly enjoy a quick break away from courtside.

Brenner is the only children's hospital in northwest North Carolina serving western North Carolina, as well as parts of Virginia, South Carolina, and Tennessee. More than 4,500 children are admitted to Brenner Children's Hospital each year and 21,000 pediatric outpatient visits occur annually at hospital-based subspecialty clinics.

Photo captions

Group
Mascots of the Atlantic Coast Conference strike a pose during their visit to Brenner Children's Hospital. The mascots stopped by as part of an outreach initiative for the 2014 ACC Men's Basketball Tournament.

Patient with Tiger
Aspiring actress Emma Miller accepts a signed basketball from the Clemson Tiger Cub. The mascots of the Atlantic Coast Conference paid a visit to Brenner Children's Hospital as part of an outreach initiative for the 2014 ACC Men's Basketball Tournament.

Video - http://origin-qps.onstreammedia.com/origin/multivu_archive/PRNA/ENR/FX-MM87893-20140320-01.mp4
Photo - http://photos.prnewswire.com/prnh/20140321/MM87893-a
Photo - http://photos.prnewswire.com/prnh/20140321/MM87893-b
Logo - http://photos.prnewswire.com/prnh/20111114/DC06171LOGO

SOURCE Wake Forest Baptist Medical Center

reade more...

Global Consumer Electronic Biometrics Market

DUBLIN, Mar. 21, 2014 /PRNewswire/ --

Research and Markets

(

http://www.researchandmarkets.com/research/2m6p4w/global_consumer

) has announced the addition of the

"Global Consumer Electronic Biometrics Market "

report to their offering.

(Logo: http://photos.prnewswire.com/prnh/20130307/600769)

The Global Consumer Electronics Biometrics market has been witnessing increasing consolidation and is expected to continue in the coming years. Both the existing vendors and new entrants prefer the acquisitive route to either enter the market or broaden their portfolio of offerings. For instance, Apple acquired AuthenTec for US$356 million in 2012, which helps Apple attain all its patents for biometrics security in mobile devices. 3M completed the acquisition of Cogent Inc. in December 2010 for US$943 million. Cogent is a maker of biometrics recognition systems that allow governments and businesses to identify individuals by their fingers, palms, faces, and irises.

According to the report, the major growth driver is increasing use of personal devices for financial transactions. Since financial institutions are encouraging the use of mobile banking and online financial transactions, the need for high-level security is increasing. Also, the use of biometrics in consumer electronics helps in providing high-level security, enabling the growing use of biometrics in consumer electronics.

Further, the report states that one of the major challenges is the availability of inexpensive non-biometrics technologies. There is a high availability of solutions such as token-based two-factor authentication, password authentications, and software authentication. They are comparatively inexpensive and are much easier to operate, thereby finding greater acceptance among individual consumers. Therefore, it affects the growth of the Global Consumer Electronics Biometrics market.

The report also includes a discussion of the other vendors operating in this market. The other vendors in the market are Panasonic Corp., Biometrics Security Ltd., Cross Match Technologies Inc., Suprema Inc. Fingerprint Cards AB, and Siemens Biometrics.

Key Topics Covered:

1. Executive Summary

2. List of Abbreviations

3. Introduction

4. Market Research Methodology

5. Scope of the Report

6. Market Description

7. Market Landscape

8. Geographical Segmentation

9. Vendor Landscape

10. Buying Criteria

11. Market Growth Drivers

12. Drivers and their Impact

13. Market Challenges

14. Impact of Drivers and Challenges

15. Market Trends

16. Key Vendor Analysis

17. Key Takeaways

18. Other Reports in this Series

Companies Mentioned:

3M Cogent Inc. AuthenTec Inc. Fujitsu Ltd. NEC Corp.
For more information visit http://www.researchandmarkets.com/research/2m6p4w/global_consumer

Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net

SOURCE Research and Markets

RELATED LINKS
http://www.researchandmarkets.com

reade more...

Healthcare Real Estate Conference New York: Join Leading Investors, Developers, Capital Sources & Healthcare Executives on April 8; Look Who's Attending

"As a real estate investor and a student of the health education program at Columbia University, I was looking forward to Healthcare & Real Estate with much anticipation. The event turned out to be more than I expected: exceptionally ...jwplayer.key="2kY/GKwZ2uQZmDlQ9VYArfZt2b4+KhHX3+DM4zisgtE=";NEW YORK, March 20, 2014 /PRNewswire-iReach/ -- If you are active in healthcare real estate investment, development and financing around the nation, you will not want to miss HEALTHCARE & REAL ESTATE 2014 on April 8 in New York. Join 40 speakers in 12 panel discussions and the expected 400+ attendees for discussion, debate and networking. Explore New Healthcare Real Estate, Medical Office Building and Research Facility Investment, Development & Financing Opportunities in Greater New York. HEALTHCARE & REAL ESTATE 2014 will bring together the leading national and Tri-State healthcare real estate executives, healthcare providers and industry service providers for a full-day market intelligence and networking program on April 8.

(Photo: http://photos.prnewswire.com/prnh/20140320/MN86779)

Confirmed Speakers: Hear New Voices & Expert Industry Analysts:

* Mark Burkemper, Senior Vice President, Harrison Street Real Estate Capital, LLC
* Jeffrey H Cooper, Chairman & Executive Managing Director, Savills
* Jeffrey P. Drucker, AIA, Vice President and Studio Director, Northeast Region, ARRAY
* Ciro Fraschilla, AIA, President & Chief Executive Officer, Mascioni & Behrmann, Architecture & Engineering, P.C.
* Wilkingson Germain, Investment Officer, Ventas, Inc.
* Morris Gross, Vice President – Facilities Management, Danbury Hospital
* Todd Jensen, Chief Investment Officer, American Realty Capital Healthcare Trust
* Christopher W. Korsh, Senior Principal – Regional Leader, Healthcare, HOK
* Steven Laufer, President, Promenade Senior Living
* Sean P. Leyden, Partner/Director, Garfunkel Wild, P.C.
* H. Guy Leibler, President, Simone Healthcare Development
* John Marshall, Vice President, Duke Realty
* Scott A. Mason, D.P.A, FACHE, Executive Managing Director and Leader | Healthcare, Cushman & Wakefield
* Chris Montello, Principal, MP Healthcare Services
* Casey N. Moore, Principal, Prudential Mortgage Capital
* Max Newland, Director – Acquisitions, Kayne Anderson Real Estate
* Paul N. Orloff, MD, President, New York County Medical Society
* Ted A. Petrillo, Principal, Westage Companies
* Gary Sastow, Law Offices of Gary S. Sastow, PLLC
* Frank R. Williams, Jr., Senior Managing Director – Acquisitions, Medical Properties Trust, Inc.
* Paul Wexler, Wexler Healthcare Properties, The Corcoran Group
* Salley Whitman, Co-Founder & Executive Director, NXT Health
* Jonathan L. Winer, Senior Managing Director and Chief Investment Officer, Seavest Healthcare Properties, LLC
* Laca Wong Hammond, Head of Healthcare Real Estate – Healthcare Investment Banking, Raymond James

For detailed agenda and registration: www.cre-events.com/HCRE2014

Participating investors, developers & owners as of March 11, include:

* American Realty Capital
* Harrison Street Real Estate Capital, LLC
* Health Care REIT, Inc.
* Healthcare Trust of America, Inc.
* Kayne Anderson Real Estate
* Lillibridge Healthcare Services
* MB Real Estate
* MedDev LLC
* Medical Properties Trust, Inc.
* Meritage Properties LLC
* Seavest Healthcare Properties, LLC
* Simone Development / Simone Healthcare
* Ventas, Inc.
* Westage Companies (partial list)

HEALTHCARE & REAL ESTATE 2014 will feature 40 speakers, including new voices and industry experts in 12 panel discussions. Agenda coverage:
* The new and changing delivery of healthcare in 2014: What's new in healthcare delivery?
* Urgent care centers update: Are they here to stay?
* Healthcare legal analysis: What are the legal ramifications of the accountable care act?
* Is the private practice of medicine going the way of the dinosaur? Who will survive and who may become extinct?
* New innovations in healthcare: What are the most profitable medical services being provided today?
* A study of healthcare design today and the efficiencies of multiple care facilities: Exploring the Importance of efficient health care design in today's multi-specialty healthcare spaces
* Investment trends in healthcare real estate, including hospitals, medical office buildings and research facilities: Who is investing in healthcare real estate today?

"The current transformation of the delivery of healthcare services from a provider oriented system to a patient centric system is revolutionizing where, how, and who is now providing healthcare services. Come learn the latest trends in healthcare real estate today: who is doing the deals, where the deals are being done, and why what is happening affects every one of us."- Paul Wexler, Wexler Healthcare Properties, The Corcoran Group

For detailed agenda and registration: www.cre-events.com/HCRE2014

NETWORKING & NEW BUSINESS DEVELOPMENT: 135 leading CRE and healthcare executives have already made plans to attend - Add your firm's name to this influential list today. 300+ are expected to attend. Attending firms, as of March 12, 2014.

AFD Contract Furniture Inc. American Realty Capital Arbor Commercial Mortgage ARRAY Array Architects Bank of America Beech Street Capital Bergman Real Estate Group Capital One Caracor LLC CBRE Cox, Castle & Nicholson LLP CTL Capital Cushman & Wakefield Danbury Hospital Dare Living Associates Duke Realty EmblemHealth, Inc. EwingCole First Columbia Property Services Garfunkel Wild, P.C. GE Capital – Healthcare Financial Services Gilsanz Murray Steficek, LLP Harrison Street Real Estate Capital, LLC Health Care REIT Health Care REIT, Inc. HealthAmerica Realty Group Healthcare Real Estate Insights HFF HOK JFK&M Consulting Group Kayne Anderson Real Estate Kings III Emergency Communications Law Offices of Gary S. Sastow, PLLC LifeQuest Lillibridge Healthcare Services LJS Real Estate Services LotInfo LLC LPCiminelli Marcus & Millichap Real Estate Investment Services Mascioni & Behrmann, Architecture & Engineering, P.C. MB Real Estate MedDev LLC Medical Properties Trust, Inc. Memorial Sloan Kettering Cancer Center Meritage Properties LLC Montefiore MP Healthcare Services NAI JAMES E. HANSON New York County Medical Society NIC NK Architects NPV Advisors NXT Health Penn Real Estate Group Platinum Health Care, LLC Promenade Senior Living Prudential Mortgage Capital Prudential Mortgage Capital Company Raymond James Savills Savills LLC Seavest Healthcare Properties, LLC Simone Development Simone Healthcare Simone Healthcare Development Spirit Realty Capital Inc. Stan Johnson Company Starwood Capital Group Stephen Yablon Architect Suburban Hospital Alliance Suffolk Construction Co., Inc. The Keith Corporation Ventas, Inc. Voikos Construction Management Westage Companies Wexler Healthcare Properties, The Corcoran Group Windels Marx Lane & Mittendorf, LLP Yang & Associates, P.C.
Event Speaker/Sponsor Contact: Brian Klebash | 917-460-3572 | info@cre-events.com
Telephone Registration/Questions: Ronnie Niederman | 212-873-3484

For more information or to get involved: info@cre-events.com | www.cre-events.com

Media Contact: Brian Klebash, CAPRATE Events, LLC, 6175016075, info@cre-events.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com

SOURCE CAPRATE Events, LLC

Avanir Pharmaceuticals Announces Appointment of Mark Corrigan to Board of Directors

Avanir Pharmaceuticals, Inc. (PRNewsFoto/Avanir Pharmaceuticals, Inc.)jwplayer.key="2kY/GKwZ2uQZmDlQ9VYArfZt2b4+KhHX3+DM4zisgtE=";ALISO VIEJO, Calif., March 19, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced the appointment of Dr. Mark Corrigan to the company's board of directors. Dr. Corrigan, a seasoned life sciences executive joins Avanir's board with broad healthcare industry experience.

Dr. Corrigan currently serves as president and chief executive officer of Zalicus Inc. a public biopharmaceutical company, a position he has held since January 2010. He has also served as a director of Zalicus and its progenitor companies since December 2006. Prior to Zalicus, Dr. Corrigan served as executive vice president, research and development at Sepracor, Inc. (now known as Sunovion Pharmaceuticals, Inc.). Prior to joining Sepracor, Dr. Corrigan spent 10 years with Pharmacia & Upjohn, a pharmaceutical company acquired by Pfizer, Inc. in 2003, most recently as group vice president of Global Clinical Research and Experimental Medicine. Prior to joining the pharmaceutical industry, Dr. Corrigan spent five years in academic research at the University of North Carolina Medical School, focusing on psychoneuroendocrinology. Dr. Corrigan has also been a member of the board of directors and audit committee of Cubist Pharmaceuticals, Inc. since June 2008. Dr. Corrigan holds a B.A. and an M.D. from the University of Virginia and subsequently received specialty training in Psychiatry at Cornell and Maine Medical Center.

"It is a pleasure to welcome Mark to the Avanir Board," commented Craig Wheeler, chairman of the board, "Mark brings many years of experience in the healthcare sector combined with a deep knowledge of CNS research and development together with broad experience in guiding the growth of biopharma companies. I look forward to the insights he will bring to our board and to working with him as Avanir pursues its growth initiatives."

About Avanir Pharmaceuticals, Inc.
Avanir Pharmaceuticals, Inc. is a biopharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need. As part of our commitment, we have extensively invested in our pipeline and are dedicated to advancing medicines that can substantially improve the lives of patients and their loved ones. For more information about Avanir, please visit www.avanir.com.

AVANIR® is a trademark or registered trademark of Avanir Pharmaceuticals, Inc. in the United States and other countries.

Avanir Investor & Media Contact
Ian Clements, PhD
ir@avanir.com
+1 (949) 389-6700

Joey Fleury, BrewLife
jfleury@brewlife.com
+1 (415) 946-1090

Logo - http://photos.prnewswire.com/prnh/20130207/LA55901LOGO

SOURCE Avanir Pharmaceuticals, Inc.

The New York Genome Center And IBM Watson Group Announce Collaboration To Advance Genomic Medicine

NEW YORK, March 19, 2014 /PRNewswire/ -- The New York Genome Center (NYGC) and IBM (NYSE: IBM) today announced an initiative to accelerate a new era of genomic medicine with the use of IBM's Watson cognitive system. IBM and NYGC will test a unique Watson prototype designed specifically for genomic research as a tool to help oncologists deliver more personalized care to cancer patients.

NYGC and its medical partner institutions plan to initially evaluate Watson's ability to help oncologists develop more personalized care to patients with glioblastoma, an aggressive and malignant brain cancer that kills more than 13,000 people in the U.S. each year. Despite groundbreaking discoveries into the genetic drivers of cancers like glioblastoma, few patients benefit from personalized treatment that is tailored to their individual cancer mutations. Clinicians lack the tools and time required to bring DNA-based treatment options to their patients and to do so, they must correlate data from genome sequencing to reams of medical journals, new studies and clinical records -- at a time when medical information is doubling every five years.

This joint NYGC Watson initiative aims to speed up this complex process, identifying patterns in genome sequencing and medical data to unlock insights that will help clinicians bring the promise of genomic medicine to their patients. The combination of NYGC's genomic and clinical expertise coupled with the power of IBM's Watson system will enable further development and refinement of the Watson tool with the shared goal of helping medical professionals develop personalized cancer care.

The new cloud-based Watson system will be designed to analyze genetic data along with comprehensive biomedical literature and drug databases. Watson can continually 'learn' as it encounters new patient scenarios, and as more information becomes available through new medical research, journal articles and clinical studies. Given the depth and speed of Watson's ability to review massive databases, the goal of the collaboration is to increase the number of patients who have access to care options tailored to their disease's DNA.

"Since the human genome was first mapped more than a decade ago, we've made tremendous progress in understanding the genetic drivers of disease. The real challenge before us is how to make sense of massive quantities of genetic data and translate that information into better treatments for patients," said Robert Darnell, M.D., Ph.D., CEO, President and Scientific Director of the New York Genome Center. "Applying the cognitive computing power of Watson is going to revolutionize genomics and accelerate the opportunity to improve outcomes for patients with deadly diseases by providing personalized treatment."

First Watson Application in Genomic Research
Watson will complement rapid genome sequencing and is expected to dramatically reduce the time it takes to correlate an individual's genetic mutations with reams of medical literature, study findings, and therapeutic indications that may be relevant. The intention is to provide comprehensive information to enable clinicians to consider a variety of treatment options that the clinician can tailor to their patient's genetic mutations. It will also help NYGC scientists understand the data detailing gene sequence variations between normal and cancerous biopsies of brain tumors.

"As genomic research progresses and information becomes more available, we aim to make the process of analysis much more practical and accessible through cloud-based, cognitive innovations like Watson," said Dr. John E. Kelly III, Senior Vice President and Director of IBM Research. "With this knowledge, doctors will be able to attack cancer and other devastating diseases with treatments that are tailored to the patient's and disease's own DNA profiles. If successful, this will be a major transformation that will help improve the lives of millions of patients around the world."

The goal is to have the Watson genomics prototype assist clinicians in providing personalized genomic analytics information as part of a NYGC clinical research study. The solution has been under development for the past decade in IBM's Computational Biology Center at IBM Research.

New York State's Investment in Genomic Medicine
New York State is at the forefront of advancing medical science and commercialization. Governor Andrew M. Cuomo recently proposed $105 million to fund a partnership between NYGC and the University at Buffalo's Center for Computational Research to advance genomics research. This investment to enhance the state's genomic medicine capabilities, together with NYGC's acquisition of Illumina's state-of-the-art HiSeq X Ten whole human genome sequencing system, will accelerate the availability of valuable genomic information in New York.

"New York State's investment in cutting-edge innovative industries is creating jobs and growing the economy in Western New York and across our state," said Governor Cuomo. "This collaboration between the New York Genome Center and IBM will help make the region a new hub for the growing bio-tech industry."

IBM is NYGC's Founding Technology Member and will advance the organization's goals of translating genomic research into clinical solutions for serious disease through the collaboration of medicine, science and technology. As biology increasingly becomes an information science, the promise of genomics is closer to reality with the help of data-driven analytics methods and more powerful computing systems. IBM and NYGC's computational biology experts are renowned for accelerating life sciences discoveries using deep analytical approaches and next generation information technologies.

Learn more about this story at http://ibm.co/1cXTb6u.

To view a Flickr image gallery that illustrates today's news please click here.

For additional perspectives on this story, please watch this video.

To join the social conversation on Twitter use the hashtag #NYGCWatson.

Journalists and bloggers can download broadcast video, b-roll and photos about the Watson and New York Genome Center collaboration at http://bit.ly/1dcWlZF. The video is available in HD, standard definition broadcast and streaming quality.

About the New York Genome Center
The New York Genome Center (NYGC) is an independent, nonprofit at the forefront of transforming biomedical research and clinical care with the mission of saving lives. As a consortium of renowned academic, medical and industry leaders across the globe, NYGC focuses on translating genomic research into clinical solutions for serious disease. Our member organizations and partners are united in this unprecedented collaboration of technology, science, and medicine. We harness the power of innovation and discoveries to improve people's lives - ethically, equitably, and urgently. Member institutions include: Albert Einstein College of Medicine, American Museum of Natural History, Cold Spring Harbor Laboratory, Columbia University, Cornell University/Weill Cornell Medical College, Hospital for Special Surgery, The Jackson Laboratory, Memorial Sloan-Kettering Cancer Center, Icahn School of Medicine at Mount Sinai, New York-Presbyterian Hospital, The New York Stem Cell Foundation, New York University, North Shore-LIJ, The Rockefeller University, Roswell Park Cancer Institute and Stony Brook University. For more information, visit: www.nygenome.org.

About IBM Watson
Named after IBM founder Thomas J. Watson, Watson was developed in IBM's Research labs and is now being accelerated into market by the new Watson Group. Watson represents a new class of software, services and apps that think, improve by learning, and discover answers and insights to complex questions from massive amounts of Big Data. Watson's ability to answer complex questions posed in natural language with speed, accuracy and confidence is transforming decision-making across a variety of industries, including health care, financial services and retail. IBM has advanced Watson from a game-playing innovation into a commercial technology. Using natural language processing and analytics, Watson processes information akin to how people think, representing a major shift in an organization's ability to quickly analyze, understand and respond to Big Data. Now delivered from the cloud and able to power new consumer and enterprise services and apps, Watson is 24 times faster, smarter with a 2,400 percent improvement in performance, and 90 percent smaller – IBM has shrunk Watson from the size of a master bedroom to three stacked pizza boxes. IBM is investing $1 billion to introduce a new class of cognitive computing services, software and apps, and investing $100 million to spur innovation for software application providers to develop a new generation of Watson-powered solutions. Learn more about IBM Watson at www.ibmwatson.com. Learn more about IBM Research at www.research.ibm.com.

Learn more about IBM healthcare at ibm.com/smarterhealthcare.

Video - http://youtu.be/xQvdR_iUDhI
Photo - http://photos.prnewswire.com/prnh/20140319/NY86161-a
Photo - http://photos.prnewswire.com/prnh/20140319/NY86161-INFO-b
Logo - http://photos.prnewswire.com/prnh/20090416/IBMLOGO

SOURCE IBM

DigitalPersona Fingerprint Readers Helping to Verify Citizen Identities in India

REDWOOD CITY, Calif., March 19, 2014 /PRNewswire/ -- DigitalPersona, Inc., a trusted partner for biometric identity verification solutions, today announced that more than 60,000 of its biometric sensors are helping millions of citizens throughout India access a variety of entitlement programs and banking services. Officials from Visiontek, a worldwide supplier of customer premised telecom equipment and software solutions, chose to incorporate the DigitalPersona® TCS1 Steelcoat sensor into handheld biometric readers for several reasons, including cost and compliance with national Standardization Testing and Quality Certification (STQC) criteria for image quality and ruggedness.

"Achieving the equally important goals of citizen convenience, fraud prevention and low program costs requires exceptional technology," said Ramesh Chunduru, director of sales and marketing for Visiontek. "We chose the TCS1 Steelcoat sensor because it consistently captures quality fingerprints in a variety of demanding environmental conditions. It also offers the most economical solution in terms of lifetime cost of ownership."

As in most banking and entitlement programs, fraudulent activities — such as ghost identities and impersonation — were creating significant operational and budgetary problems for both financial institutions and government agencies. After studying a number of options, Visiontek chose to address those problems with fingerprint biometrics built around the DigitalPersona sensor.

Field officers use handheld devices to scan fingerprints of citizens who want to access banking services, entitlement programs and other privileges that require assured identification. Scanned images are compared to identity data stored in one of three places — a secure central database, a smart card carried by citizens or in a point of sale (POS) terminal.

Confirmed identities are used to grant access to food distribution programs for Indian citizens and microfinance products for consumers who were previously "unbanked." The readers are also used to verify both performance and payment in the Mahatma Gandhi Rural Employment Guarantee Scheme (MGNREGS).

"We're proud to be part of programs that bring entitlements to Indian citizens and financial inclusion to people who previously had no access to banking services," said Richard Agostinelli, DigitalPersona president and CEO. "Because the Indian government has chosen biometrics as the preferred method of secure identification — and because the TCS1 is the only STQC-certified silicon sensor on the market — we expect our involvement in these critical programs will continue to grow."

The TCS1 fingerprint sensor offers an exceptionally large image capture area, which helps ensure the best possible biometric performance. The popular sensor is being used for a variety of public and private applications worldwide, including logical and physical access control, mobile transactions, time-and-attendance and law enforcement.

"Clearly, integrators and end-users are placing lots of emphasis on quality image capture, device ruggedness and low total cost of ownership," Agostinelli said. "We believe that's why the TCS1 sensor is being selected for so many secure identity programs worldwide."

About DigitalPersona
DigitalPersona offers the world's broadest portfolio of biometrics-based identity verification solutions. Applications range from highly secure banking environments and complex government identity programs to point-of-sale retail systems. Our solutions verify the identity of more than 200 million authorized users worldwide and significantly reduce the risk of fraud, theft and unauthorized access. Offerings for end-users and system integrators include industry-specific software applications, complete SDKs and a full range of optical, silicon, touch, swipe and embedded readers. For more information call +1 650.474.4000 or send an email to pr@digitalpersona.com.

SOURCE DigitalPersona, Inc.

RELATED LINKS
http://www.digitalpersona.com

reade more...

Monterey Program of Executive Health Offers World-Class Medicine, World-Class Destination

MONTEREY, Calif., March 19, 2014 /PRNewswire/ -- A distinctive program designed to give clients an efficient and comprehensive medical evaluation in one of the most coveted resort and golf destinations in the country, The Monterey Program for Executive Health approaches preventative medical care with patients' time and comfort in mind. The elite physicians at The Monterey Program spend a full day with the patient to complete comprehensive screening, imaging and other advanced diagnostics—all in a sanctuary setting.

In addition to undergoing the most advanced diagnostics in the medical industry, the client is given a comprehensive risk-factor assessment that analyzes family and patient medical histories and current lifestyle habits. Experienced, licensed professionals evaluate the status of patients' nutrition and fitness levels and work with the physicians to create tailored lifestyle suggestions that integrate seamlessly into their often busy daily routines. The client and doctor will then work together to develop a personalized wellness plan that includes a discussion of risk factors and illness prevention.

When the evaluation is complete, the client receives an extensive, customized medical report with a health profile, results, interpretations and recommendations for follow-up care. This detailed report of the patient's evaluation is conveniently stored as a digital file on a small flash drive.

As an additional service, the Monterey Program offers corporate packages for businesses to provide to their top executive officers. The program can turn essential preventative care into a productive and relaxing corporate retreat.

Get Fit This Spring

Kick off spring with a healthy start by getting the right gear, revamping your routine and doing some "spring cleaning" in your pantry.

Here are some tips from Dr. Geiler and his team:

Get an Annual Check Up. It's important to keep tabs on things like blood pressure, cholesterol, and vitamin deficiencies before designing your workout program. Clean Out Your Pantry. Throw away other foods low in nutritional value, like chips, pretzels, sugary cereals and white bread. After you clean out the pantry, hit the farmers market. Shop for fresh fruits and veggie as well as fish, dried fruits and nuts. Change your diet. Add high-protein, healthy nuts and seeds for a great healthy energy boost! Get out and exercise. Make it fun. Find an activity that you enjoy. Find a buddy. Having an exercise partner can keep you more accountable. Schedule it. Make an appointment with exercise and don't cancel it."At the Monterey Program for Executive Health we encourage our clients to make good food, exercise and lifestyle choices, and you'll get to enjoy a makeover that'll last a lifetime," said Dr. Geiler. "Our goal at the Monterey Program is to help our clients fully understand their medical picture, so they can convert that knowledge into action."

The Monterey Program For Executive Health Contact:

SOURCE Monterey Program For Executive Health

RELATED LINKS
http://www.mpexecutivehealth.com

reade more...

NexID First To Offer "Liveness Detection" Software For Mobile Devices

WASHINGTON, March 18, 2014 /PRNewswire/ -- As mobile device manufacturers embed fingerprint ID into millions of smartphones, NexID Biometrics today introduces its Mobile Live Finger Detection (LFD) software, the first liveness detection solution designed specifically to exceed the convenience and security needs of mobile users worldwide. The software provides authentication rates as high as 94-97 percent, offering the highest levels of "spoof-proofing" software available on the market today.

NexID developed the Mobile LFD software solution specifically for mobile devices. Due to the variety of fingerprint-scanning solutions on the market, the company designed the software to be technology agnostic so it could work with all fingerprint sensors and mobile devices, while achieving fast execution times and resource efficiency.

The Mobile LFD software resides in a mobile device and detects whether an image captured by the device's fingerprint sensor is detecting a finger from a living person or if it's a fake or "spoofed" fingerprint.

Adding live finger detection enhances the device's security and helps eliminate unlocking a phone or one of its applications that may contain confidential information. As evidenced with Apple's iPhone 5S TouchID, fingerprint sensors are actually highly vulnerable to hacking without some form of liveness detection.

NexID will introduce Mobile LFD here this week in Booth #202 at the Connect: ID Expo, where company executives will discuss and illustrate fingerprint spoofing techniques and fake finger detection. Additionally, Clarkson University professor and NexID co-owner, Dr. Stephanie Schuckers, will be speaking at the conference at 1:50 p.m. today on the topic of "Fake Fingers and Stolen Templates: Topics in Biometric Security."

"Two of the world's leading mobile device makers now include fingerprint identification on their devices, so it doesn't take a crystal ball to see that trend continuing," said NexID COO Mark Cornett. "We believe every mobile device will incorporate some type of fingerprint ID functionality in the next couple of years. And with people relying more and more on their devices, the security of personal, financial, health and business information is not just needed, it's imperative. "

For example, businesses contemplating adopting Bring Your Own Device (BYOD) programs face the need to ensure company information on mobile devices remains private and secure; meanwhile, employees may opt for more convenience to access phone features on the same devices. Mobile LFD offers a sliding scale of security for fingerprint ID on smartphones, allowing for a simple and flexible solution.

NexID said its Mobile LFD can immediately enhance the myriad of fingerprint ID solutions being developed by sensor manufacturers, mobile devices companies, and application developers. Fingerprint sensor companies can embed the software directly onto a sensor's chip (LFD on chip), and device manufacturers can add it to the main processor (LFD on host), all to provide customers with a convenient alternative to traditional PINs and passwords. NexID's Mobile LFD solution can also be embedded in "trust zone" or trusted execution environment chip sets.

The Mobile LFD SDK will be distributed free for evaluation, solution integration, and testing purposes. NexID also offers professional services to assist with the solution integration process. Licensing and distribution agreements are negotiated separately.

For more information on NexID Mobile LFD, please visit www.nexidbiometrics.com. A white paper on liveness detection, including examples of how the company researches and tests different "spoofing" techniques, is also available.

About NexID Biometrics
NexID Biometrics is a leading software and technology supplier to the biometric authentication industry. The company develops and licenses liveness detection software that enables fingerprint-scanning technologies to more accurately, and with greater confidence, authenticate scanned images by mitigating spoof-related risks. The company also provides testing and analysis of fingerprint scanning devices to identify existing vulnerabilities to known spoofing strategies. The company's founders represent some of the world's leading authorities on biometric spoof mitigation and liveness detection.

Logo - http://photos.prnewswire.com/prnh/20131016/SF97206LOGO

SOURCE NexID Biometrics

reade more...

Biometric Border Controls Failed the Passengers of Malaysia Airlines Flight 370

DENVER, March 18, 2014 /PRNewswire/ -- Had Malaysia - the world's first country to introduce biometric ePassports and a leader in automated border control eGates - biometrically verified passengers, those with false travel documents and any terror suspects could have been identified before boarding Malaysia Airlines Flight 370.

At least two passengers with stolen passports slipped past security.

According to Maxine Most, biometric identity and security technology expert, "Had the Kuala Lumpur International Airport employed biometric authentication for everyone with access to airplanes, investigators would have a reliable record of every individual - passengers, crew, and workers - who accessed the aircraft prior to take off. These measures may not have prevented the disappearance of Malaysia Airlines Flight 370, but they may very well prevent similar tragedies in the future."

"While the billions of dollars spent on biometric passports, visas, and automated border controls since 9/11 have made us safer," says Most, a Principal of Acuity Market Intelligence. "More must be done to make sure the biometric technology we have is actually used."

Most says, "Government agencies increasingly rely on biometrics to issue and validate passports and visas, and monitor border crossings. However, transitioning to a comprehensive biometric-based border management and aviation security system is a complex process that, unfortunately, takes time."

Most's Acuity Market Intelligence reports that by the end of 2014, 110 countries will have issued more than 700 million biometric ePassports representing 83% of all those in circulation and 66 countries will require visa applicants to submit biometrics.

The United States is among 10 countries that collect biometrics from all foreign visitors when they enter the country with many more likely to do so over the next five years. In addition, more than 150 airports currently have some form of automated border control eGates or kiosks that either rely on ePassports or require separate biometric registration. This number will double by 2020.

For more insight into biometric border control, preview Acuity's latest report "The Automated Border Control Industry Report: Airport eGates and Kiosks at www.acuity-mi.com/Research_Reports.php

About Acuity Market Intelligence ?Acuity Market Intelligence (http://www.acuity-mi.com) is an emerging technology strategy and research consultancy with a proven record of accurately anticipating biometric and electronic identity (eID) market trends.

Contact:
Acuity Market Intelligence
+1 303 449 1897 ?

SOURCE Acuity Market Intelligence

Kimberly-Clark Health Care and 3M Announce U.S.-Based Infection Prevention Solutions Agreement

Kimberly-Clark Health Care. (PRNewsFoto/Kimberly-Clark Health Care)jwplayer.key="2kY/GKwZ2uQZmDlQ9VYArfZt2b4+KhHX3+DM4zisgtE=";ROSWELL, Ga. and ST. PAUL, Minn., March 17, 2014 /PRNewswire/ -- Kimberly-Clark Health Care and 3M Infection Prevention Division today announced a unique alliance to deliver best-in-class surgical and infection prevention solutions to hospitals and healthcare facilities in the U.S.

"At Kimberly-Clark, we have long admired 3M's track record of innovation. This relationship presents the opportunity to offer a more extensive surgical product portfolio with the latest healthcare technology to help customers tackle their foremost challenges including infection prevention and hospital readmissions," said Chris Lowery, Global VP, Health Care Sales & Marketing, Kimberly-Clark. "Together, Kimberly-Clark and 3M will leverage our respective expertise to bring forward solutions that address our customers' most critical needs in the operating room."

"Kimberly-Clark offers tremendous experience and long-standing relationships built around a consultative approach in the operating room and we are thrilled to work together. 3M's history of innovative products, paired with Kimberly-Clark's expertise, will create an exceptional offering for our healthcare customers," added Silvia Perez, Global Business Vice President, Infection Prevention Division, 3M. "By working with a like-minded company equally committed to addressing current healthcare challenges, we are harnessing our collective capabilities to improve surgical outcomes."

With the launch of the collaboration, Kimberly-Clark Health Care will offer 3M™ Steri-Drape™ fabric and plastic specialty drapes, featuring drapes with and without 3M™ Ioban™ 2 Antimicrobial Incise Film, which provides excellent adhesion throughout the surgical site and helps reduce the risk of wound contamination. The addition of the 3M drape line rounds out Kimberly-Clark Health Care's surgical and infection prevention offering. All 3M Steri-Drape surgical drapes will be available through the same distribution and surgical pack manufacturing channels as they are today.

About 3M
3M captures the spark of new ideas and transforms them into thousands of ingenious products. Its culture of creative collaboration inspires a never-ending stream of powerful technologies that make life better. 3M is the innovation company that never stops inventing. With $31 billion in sales, 3M employs 89,000 people worldwide and has operations in more than 70 countries. For more information, visit www.3M.com or follow @3MNews on Twitter.

About 3M Health Care
3M Health Care offers solutions in the medical, oral care, drug delivery, food safety and health information markets. We have an unparalleled ability to connect people, insights, science and technology to think beyond today, solve problems, and make better health possible. Our culture of collaboration empowers us to discover and deliver practical, proven solutions that enable our customers to protect and improve the health of people around the world.

About Kimberly-Clark
Kimberly-Clark Corp. (NYSE: KMB) and its well-known global brands are an indispensable part of life for people in more than 175 countries. Every day, nearly a quarter of the world's population trust K-C's brands and the solutions they provide to enhance their health, hygiene and well-being. With brands such as Kleenex®, Scott®, Huggies®, Pull-Ups®, Kotex® and Depend®, Kimberly-Clark holds the No. 1 or No. 2 share position in more than 80 countries. To keep up with the latest K-C news and to learn more about the Company's 142-year history of innovation, visit www.kimberly-clark.com or follow us on Facebook or Twitter.

Kimberly-Clark in the Healthcare Environment
Around the world, medical professionals turn to Kimberly-Clark for a wide portfolio of solutions that improve the health, hygiene and well-being of their patients and staff. As part of their healing mission, caregivers rely on Kimberly-Clark to deliver clinical solutions, hygiene & cleaning offerings, and educational resources that they can depend on to prevent, diagnose and manage a wide variety of healthcare-associated infections. A global enterprise of more than $1 billion, Kimberly-Clark Health Care holds the No. 1 or No. 2 market share position in several categories, including infection control solutions, surgical solutions, pain management, hygiene solutions, digestive health and respiratory health. And throughout the care continuum, patients and staff alike trust Kimberly-Clark medical supplies and devices, KLEENEX® tissues, KLEENEX® & SCOTT® skin care products and SCOTT® towels for day-to-day needs. For more information, visit http://www.kchealthcare.com and http://www.kcprofessional.com.

[KMB-B]

Logo - http://photos.prnewswire.com/prnh/20140317/DA83944LOGO
Logo - http://photos.prnewswire.com/prnh/20110928/DA76879LOGO

SOURCE Kimberly-Clark Health Care

RELATED LINKS
http://www.kchealthcare.com

reade more...

Pages

.